Track Finch Therapeutics Group's accounts payable ($29K) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (June 2024), FNCH shows a accounts payable of $29K. That compares with $430K in the prior-year period — down 93.3% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, FNCH's accounts payable is now $29K (was $430K) — a 93.3% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Finch Therapeutics Group is outperforming or lagging.
Tracking FNCH's accounts payable over time shows whether Finch Therapeutics Group is scaling, shrinking, or reshaping that part of the business. The current reading is $29K That compares with $430K in the prior-year period — down 93.3% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this accounts payable page, Stockcircle has Finch Therapeutics Group's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect accounts payable (currently $29K) with ownership activity and broader fundamentals.
Finch Therapeutics Group's accounts payable is $29K; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.